Indication
Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies
Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies is a severe, relapsing autoimmune astrocytopathy of the central nervous system that predominantly targets the optic nerves, spinal cord, and brainstem. Read more about Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies
5 drugs 4 manufacturers
Drugs that treat it
Common Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies therapies.
ULTOMIRIS (ravulizumab-cwvz)
UPLIZNA (inebilizumab-cdon)
ENSPRYNG (satralizumab-mwge)
UPLIZNA (inebilizumab-cdon)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNeuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies is a severe, relapsing autoimmune astrocytopathy of the central nervous system that predominantly targets the optic nerves, spinal cord, and brainstem.
Pathophysiologically, circulating immunoglobulin G autoantibodies bind to aquaporin-4 water channels on astrocyte end-feet, triggering complement-mediated inflammation, secondary demyelination, and neuronal death.
Clinically, affected individuals experience recurrent neuroinflammatory attacks characterized by severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome presenting with intractable nausea and hiccups, which frequently lead to cumulative, permanent visual and motor disabilities.
- prnewswire.com
Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies is a severe, relapsing autoimmune astrocytopathy of the central nervous system that predominantly targets the optic nerves, spinal cord, and brainstem Clinically, affected individuals experience recurrent neuroinflammatory attacks characterized by severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome presenting with intractable nausea and hiccups, which frequently lead to cumu...
- practicalneurology.com
Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies is a severe, relapsing autoimmune astrocytopathy of the central nervous system that predominantly targets the optic nerves, spinal cord, and brainstem Pathophysiologically, circulating immunoglobulin G autoantibodies bind to aquaporin-4 water channels on astrocyte end-feet, triggering complement-mediated inflammation, secondary demyelination, and neuronal death
- nih.gov
Pathophysiologically, circulating immunoglobulin G autoantibodies bind to aquaporin-4 water channels on astrocyte end-feet, triggering complement-mediated inflammation, secondary demyelination, and neuronal death
- ultomirishcp.com
Pathophysiologically, circulating immunoglobulin G autoantibodies bind to aquaporin-4 water channels on astrocyte end-feet, triggering complement-mediated inflammation, secondary demyelination, and neuronal death Clinically, affected individuals experience recurrent neuroinflammatory attacks characterized by severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome presenting with intractable nausea and hiccups, which frequently lead to cumulative, permanent...
- nih.gov
Clinically, affected individuals experience recurrent neuroinflammatory attacks characterized by severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome presenting with intractable nausea and hiccups, which frequently lead to cumulative, permanent visual and motor disabilities
- nmosd.com
Clinically, affected individuals experience recurrent neuroinflammatory attacks characterized by severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome presenting with intractable nausea and hiccups, which frequently lead to cumulative, permanent visual and motor disabilities
Personalize your experience
Follow Neuromyelitis optica spectrum disorder with anti-aquaporin-4 (AQP4) antibodies and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.